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We present the first reported case of left ventricular assist device (LVAD) pump
thrombosis in the setting of the coronavirus pandemic. We describe the clinical
features of the case which helped to differentiate coronavirus disease 19 (COVID19) from LVAD pump thrombosis. The patient is 56-year-old female supported by
destination LVAD therapy. She was originally implanted with a HeartMate II device
in 2015 and underwent two pump exchanges in 2017 and 2019 for pump
thrombosis, despite medication adherence. Shortly after routine lab work revealed
near doubling of her lactate dehydrogenase (LDH) levels, she tested positive for
COVID-19. She then developed power spikes and symptomatic heart failure,
which prompted hospital admission. An initial computed tomography (CT) scan
showed bilateral ground glass opacities, but repeat testing was negative for
COVID-19. Her LVAD pump thrombosis was treated with aspirin, unfractionated
heparin, and cangrelor, which was guided by thromboelastogram. Over several
weeks, her LDH returned to baseline, and she was transitioned from cangrelor to
ticagrelor and from heparin to warfarin. A repeat CT scan after several days of IV
diuresis showed resolution of the ground glass opacities.
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Background
The coronavirus disease 2019 (COVID-19) pandemic creates unique challenges, as
it complicates the diagnosis of common medical problems. In general, infection is
known to frequently precede pump thrombosis in patients on left ventricular assist
device (LVAD) support,1 but the potential role of coronavirus in precipitating pump
thrombosis is unknown. We present the case of pump thrombosis in a patient with
COVID-19 infection.

Case Series Description
A 56-year-old female with history of ischemic cardiomyopathy and morbid obesity
received a HeartMate II (HMII) device (Abbott Laboratories, Abbott Park, IL) in 2015
as destination therapy. Her course was complicated by two episodes of pump
thrombosis at 23 months and 55 months post-implantation. Each episode required
a pump exchange.
During a routine laboratory check in 2020, it was noted that her lactate
dehydrogenase (LDH) increased to 1727 Units/Liter (baseline LDH in 800-900s
U/L). Since she had no other symptoms, the test was repeated 2 days later, and her
LDH returned to baseline level of 802 U/L at that time. Within a week, she developed
a fever, mild cough, myalgias, fatigue and tested positive for COVID-19. Since her
symptoms were mild, she was advised to self-quarantine at home without any
additional medications. During this time, the patient’s international normalized ratio
(INR) remained within therapeutic range (2-3). After 14 days of quarantine, the
patients LDH showed a persistent elevation at 1722 U/L. Analysis of the LVAD’s log
file captured a single elevated power of 10 W about 10 days after patient was
symptomatic with COVID-19 infection (Figure 1). At this point she was transferred
to our center for further evaluation.
Figure 1. The log file of the left ventricular assist device recorded a single power
spike (arrow).
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Upon admission, the physical exam was significant for a multi-tonal hum on
auscultation, instead of the monotonic hum of HMII. The patient was afebrile, an
oxygenation saturation of 94% on room air, a mean arterial pressure of 70 mmHg
and a heart rate of 80 beats per minute. The following day, the patient became
progressively more dyspneic with activity, had crackles on auscultation, and was
hypoxic
requiring
oxygen.
She
was
tested
for
COVID-19
by
nasopharyngeal/oropharyngeal swab upon admission and again a few days later,
both tests returned negative. The differential diagnosis at this point was pump
thrombosis with heart failure versus worsening of the COVID-19 infection. The
computed tomography (CT) angiography of the chest revealed patchy bilateral
ground glass opacities throughout both lungs in a pattern concerning for COVID-19
(Figures 2) or acute pulmonary edema. There was no thrombus in the inflow and
outflow cannulas, raising concern for thrombosis in the pump itself. An
echocardiogram showed a dilated left ventricle with end diastolic diameter of 5.8 cm
and a dilated hypokinetic right ventricle.

Figure 2. Computed tomography (CT)
angiogram of the chest that depicts bilateral
ground glass opacities. A) Frontal plane
view B) Transverse plane view

A

B

She was started on diuretics, milrinone, and heparin. Her dual antiplatelet regimen
of aspirin (81 mg daily) and dipyridamole (75 mg three times daily) was continued.
Thromboelastography (TEG) was suggestive of inadequate inhibition of platelets;
hence, dipyridamole therapy was discontinued and cangrelor was initiated at a dose
of 0.75 mcg/kg/min.
With the combination of cangrelor and heparin, both the patient’s LDH and free
hemoglobin trended down (Table 1). There was marked clinical improvement, and
she was able to be weaned off diuretics and inotropic therapy by post-admission
days 7 and 10, respectively. As clinical improvement was seen along with an
improving LDH, cangrelor was transitioned to ticagrelor. A loading dose of ticagrelor
was administered just prior to discontinuation of the cangrelor drip,
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ADP - adenosine phosphate; MA - maximal amplitude; AA - arachidonic acid; LY30 - lysis at 30 minutes
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followed by standard dosing of 90mg twice daily, replacing dipyridamole therapy.
Warfarin was reinitiated at this time with the heparin drip continuing until the INR
reached a target goal of 2.5-3.5.
Figure
3.
Transverse
plane
computed tomography angiogram
chest after several days of diuresis
showing near resolution of ground
glass opacities

Her condition improved, and she was ambulating well on room air. A repeat CT scan
of the chest showed marked improvement of the patient’s bilateral ground glass
opacities (Figure 3). The repeat echocardiogram showed a left ventricular end
diastolic diameter of 4.9 cm and improved right heart function (Figure 4). A right
heart catheterization was performed after hemodynamic stabilization showed a right
atrial pressure of 6/3 mmHg and a mean pulmonary capillary wedge pressure of 6
mmHg. Prior to discharge, the LDH was at baseline (607 U/L), free hemoglobin was
2 mg/dL, and LVAD function was stable. TEG values while on the cangrelor infusion
showed a more inhibited adenosine diphosphate arm compared to the TEG on
admission. The patient was discharged home on warfarin (INR goals remained at
2.5-3.5), ticagrelor (90 mg twice daily), and aspirin (81 mg daily).
Figure 4. Echocardiogram upon presentation with LV dilatation. (Left panel). The
echocardiogram after treatment of pump thrombosis (right panel). Both are in the
parasternal long axis.
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Discussion
Pump thrombosis is a complication of LVAD implantation, affecting approximately
5% of patients.2 It can present with clinically significant hemolysis, device alarms,
left heart failure, and cardiogenic shock. Our patient had symptoms of fatigue,
shortness of breath, hypoxia, dry cough, elevated LDH, and bilateral ground glass
opacities in the setting of a recently positive COVID-19 test. All of these symptoms
could be seen in both pump thrombosis and COVID-19 infection. T Ai et al.
reported on a series of patients with an initially negative PCR test showed signs
with COVID-19 on CT and subsequently became PCR positive.3 Thus, the
negative PCR test upon admission did not rule out the possibility of an active
COVID-19 infection.
An LDH elevation is common in patients with COVID-19, and multiple retrospective
analyses have shown a correlation between the degree of LDH elevation and
outcome.4,5 Zhou et al. found that survivors of COVID-19 had a modest elevation
of LDH, with an average value of 253 U/L, whereas non-survivors had an average
of 521 U/L, ranging as high as 669 U/L.5 In a case series of 1099 patients, Guan et
al. reported that among patients with LDH levels of greater than 250 U/L, 70.5%
met the primary endpoint, which was a composite of intensive care unit (ICU)
admission, mechanical ventilation, or death, compared to 39% of patients with a
lower LDH.5 At the same time, LDH is the principal laboratory marker used to
diagnose LVAD thrombosis. Pump thrombosis is generally suspected in HMII
patients when the LDH level is greater than 600 U/L.
The presence of ground glass opacities is another non-specific symptom.
However, ground glass opacities have been reported to be among the most
common radiologic findings in COVID-19, occurring in about half of patients;1,4-6
they are also commonly seen in pulmonary edema. Cell-free hemoglobin
elevations have also been shown to occur and predict poor outcomes in sepsis in
non-LVAD patients.7
In general, infection is an inflammatory event that can lead to a systemic
hypercoagulable state, increasing the incidence of LVAD pump thrombosis. Many
studies have shown that infection increases the risk of thrombotic complications of
LVAD.1,8 This risk is seen within six weeks of a major infection.8 Our patient had a
prior history of pump thrombosis; however, we suspected the current episode was
triggered by the preceding COVID-19 infection. In retrospect, the COVID-19
infection had likely resolved by the time she was hospitalized for the thrombotic
event.
Coagulopathy is a widely reported phenomenon in COVID-19, with high rates of
venous and arterial thrombus formation.9,10 Klok et al. reviewed 184 ICU patients
with COVID-19 and found that 35% of them had pulmonary embolism and 3.8%
had arterial thrombotic events.9 Similarly, Merkler et al. reported a stroke rate of
1.6% in COVID-19 patients presenting to the ED.11 There are emerging case
reports of patients in their 30s with COVID-19-induced strokes.12 Indeed, our
patient’s LDH nearly doubled eight days prior to the COVID-19 diagnosis,
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suggesting the virus may have exacerbated or even precipitated the pump
thrombus.
In our analysis, the most helpful clinical clues to the eventual diagnosis of pump
thrombosis in the setting of recent COVID-19 diagnosis were the degree of LDH
elevation and the power spikes. LDH is rarely reported in excess of 600 U/L, even
in high mortality cases from COVID-19. Given the acute surge in this patient to a
peak value of 2287 U/L, we felt this was better explained by pump thrombosis, and
that her COVID-19 had likely resolved by this point. Resolution of the ground glass
opacities after diuresis (Figure 3) further supported pump thrombosis and not
ongoing COVID-19.
Medical management of pump thrombosis typically includes heparin monotherapy,
direct thrombin inhibitors, thrombolytic agents, and/or glycoprotein IIb/IIIa
inhibitors. The use of escalated therapies has been more successful than heparin
alone in a number of cases; however, there is also a higher rate of bleeding seen
with these agents.13 Cangrelor is a reversible P2Y12 inhibitor that is structurally
and functionally similar to the more commonly used oral P2Y12 inhibitor,
ticagrelor. Cangrelor rapidly blocks adenosine diphosphoate-mediated platelet
aggregation and has a very quick onset of action with a short half-life. Our center
has utilized cangrelor in combination with heparin for suspected pump thrombosis
and have reported successful outcomes in at least two patients.14 In combination
with other markers (i.e., LDH, pump parameters), our center has utilized TEGdirected decision making to guide antiplatelet therapies for our LVAD patients.
Although use of cangrelor at our center is rare and has not been directly compared
to alternative agents, it has shown potential over previously described strategies in
lowering LDH in suspected pump thrombosis while possibly providing a lower
bleeding risk.
In summary, this is the first case of pump thrombosis reported in a LVAD patient
after COVID-19 infection. Our case is also unique in that we were able to medically
manage the thrombosis with the combination of cangrelor and heparin. Earlier,
Singh et al. proposed a registry of COVID-19 infection in LVAD population.15 We
agree that such registry is needed for defining the cardiovascular effects in this
special LVAD patient population.
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